Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : RELAX-HF (Michael FELKER)
- document 1 document 2 document 3
- niveau 1 niveau 2 niveau 3
- audio 1 audio 2 audio 3
Descriptif
MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012:HEART FAILURE TRIALISTS WORKSHOPLEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS
Chairpersons: Alexandre MEBAZAA, Paris, FRA - Christopher O’CONNOR, Durham, USAWebcast: Daniela DOBRE, Nancy, FRADecreasing the very high mortality and rate of re-hospitalization associated with acute worsening HF is one of the most important unmet needs in cardiovascular medicine. Despite positive signals in Phase II studies, no drug has proven to reduce the appallingly high mortality or readmission rates. The reasons for these ‘failed’ trials are multiple, including the adequacy of candidate drugs, dosing, patient selection and disease characterization, and trial conduct. The phenotypes and pathophysiology of the syndrome are poorly understood. The syndrome is heterogeneous and the taxonomy is complex and remains without a consensus. Hospitalization for acute worsening HF is understood by some as the result of progressive worsening of chronic HF and by others as an entity which acuteness has been compared to what is acute coronary syndrome to chronic coronary artery disease. Some believe that hospitalizations for HF do not represent a distinct pathophysiology than chronic HF and could be better managed by the optimization of chronic HF neurohumoral therapy. On the other hand although there are no data to support that short-term in-patient therapeutic approach improves post-discharge clinical outcomes, some speculate that protecting the injured heart during the acute process might have long term benefit. Alleviating dyspnea is still considered by regulatory agents as an endpoint valid in itself, as far as there is no excess of deaths. However most patients improve with standard therapy and the magnitude of additional dyspnea relief by the investigational drug might be marginal and therefore hardly statistically detectable. Alternative ways to test for and/or quantify dyspnea have been investigated with the aim to define a dyspnea measure that is more sensitive to change.RELAX-HF and ASTRONAUT are two trials whose results have just been announced. Both exemplify the issues highlighted here above. RELAX-HF is a phase II/III trial design trial of 48 hour IV infusion of relaxin for the treatment of signs and symptoms in patients hospitalized for acute decompensated HF (no EF criteria). ASTRONAUT evaluates the 6 months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality when initiated early afterhospitalization for acute decompensated HF and low EF. Results of PRONTO are now available. PRONTO is a randomized trial comparing the potent and rapid acting calcium channel blocker Clevidipine vs. SOC for the ability to rapidly control blood pressure and provide dyspnea relief in acute heart failure patients. PRONTO examplifies yet another trial model: intervening within the first 2 hours after admission. Lessons learnt from RELAX-HF and PRONTO within the context of other recent trials in acute heart failure will be the main topic of brainstorming at this workshop, examining the potential change in paradigm in this area.The aim of this workshop is to learn from the PRONTO, RELAX-HF and ASTRONAUT experiences within the context of the other acute HF trials, understand the consequences of the results on the design of future trials, revision of regulatory guidlenes and on possible regulatory labeling on clinical practice.The various drug intervention optionsRELAX-HF, Omecamtiv mecarbil and other drug still on trialSpeaker: Michael FELKER, Durham, USAASTRONAUTSpeaker: Aldo MAGGIONI, Florence, ITAExecution issues. Where best to screen and enroll patients? Overcoming variations in health care systems and globalization issuesSpeaker: Mihai GHEORGHIADE, Chicago, USAPRONTO: The merit and consequences of a very early intervention with an arterial vasodilatorSpeaker: Frank PEACOCK, Cleveland, USAEndpoint related issues. The value of dyspnea as an endpoint in acute HF, upon admission trialsSpeaker: Alexandre MEBAZAA, Paris, FRAThe value of repeat events in post discharge hospitalized HF trialsSpeaker: Stuart POCOCK, London, GBRRegulatory viewpoint: Yuki ANDO, PMDA, JAP - Robert HEMMINGS, MHRA, GBR
Thèmes
Notice
Documentation
Liens
Dans la même collection
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answe…StroesEric
MODIGLIANI Workshop 5 - Saturday December 1st, 2012 THE ATHEROSCLEROSIS TRIALISTS FORUM Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR Webcast: Tabassome SIMON, Paris, FRA
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story …
MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : The Vaptans story …AbrahamWilliam T.
MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Ultrafiltration fo…
MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 5 : Insights from DOSE…
MODIGLIANI Debate Session 5 - Saturday December 1st, 2012 NOVEL DIURETIC STRATEGIES IN HEART FAILURE Chairpersons: Keld KJELDSEN, Copenhagen, DEN - Gian Paolo ROSSI, Padua, ITA Webcast: Patrick
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : What endpoint for …PinaIleanaFarbAndrew
MODIGLIANI Debate Session 4 - Saturday December 1st, 2012: HEART FAILURE REMOTE MONITORING TRIALS Chairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USA Webcast: Daniela DOBRE, Nancy,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Debate Session 4 : Treatment optimiza…AbrahamWilliam T.
MODIGLIANI Debate Session 4 - Saturday December 1st, 2012: HEART FAILURE REMOTE MONITORING TRIALS Chairpersons: Stefan ANKER, Berlin, GER - Ileana PIÑA, New York, USA Webcast: Daniela DOBRE, Nancy,
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Will we be able to answe…RosensonRobert
MODIGLIANI Workshop 5 - Saturday December 1st, 2012 THE ATHEROSCLEROSIS TRIALISTS FORUM Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR Webcast: Tabassome SIMON, Paris, FRA
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets:…KoenigWolfgang
MODIGLIANI Workshop 5 - Saturday December 1st, 2012 THE ATHEROSCLEROSIS TRIALISTS FORUM Chairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBR Webcast: Tabassome SIMON, Paris, FRA
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : Regulatory viewpoin…AndoYuki
MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : The value of repeat…PocockStuart J.
MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre
-
Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Lunch Session 3 : ASTRONAUT (Aldo MAG…
MODIGLIANI Lunch Debate Session 3 - Saturday December 1st, 2012: HEART FAILURE TRIALISTS WORKSHOP LEARNING FROM RECENT TRIALS AND SHAPING THE FUTURE OF HEART FAILURE TRIALS Chairpersons: Alexandre
Sur le même thème
-
Journées EMOIS Nancy 2017 - Session F-1- Hospitalisations et mortalité des jeunes vivant avec une …
Titre : Journées EMOIS Nancy 2017 - Session F-1- Hospitalisations et mortalité des jeunes vivant avec une pathologie chronique en France : analyse à partir de l’Échantillon Généraliste des
-
Journées EMOIS Nancy 2017 - Session F-1 - Hospitalisations et mortalité des jeunes vivant avec une …
Titre : Journées EMOIS Nancy 2017 - Session F-1 - Hospitalisations et mortalité des jeunes vivant avec une pathologie chronique en France : analyse à partir de l’Échantillon Généraliste des
-
Journées EMOIS Nancy 2017 - Session F-1 - Dépistage précoce du diabète après une grossesse marquée …
Titre : Journées EMOIS Nancy 2017 - Session F-1 - Dépistage précoce du diabète après une grossesse marquée par un diabète gestationnel Intervenant(e)(s) : Karin GOUESLARD, CHU de Dijon-Bourgogne
-
Journées EMOIS Nancy 2017 - Session F-1 - Évaluation de la fiabilité du PMSI pour l’identification …
Titre : Journées EMOIS Nancy 2017 - Session F-1 - Évaluation de la fiabilité du PMSI pour l’identification des morts maternelles intra hospitalières en France Intervenant(e)(s) : Monica SAUCEDO
-
Journées EMOIS Nancy 2017 - Session F-1- Une nouvelle méthodologie pour une identification exhausti…
Titre : Journées EMOIS Nancy 2017 - Session F-1 - Une nouvelle méthodologie pour une identification exhaustive dans le PMSI des femmes admises en unités de réanimation et/ou de soins intensifs
-
Journées EMOIS Nancy 2017 - Session E-1 - Hépatotoxicité de l’Agomélatine (Valdoxan®) en comparaiso…
Titre : Journées EMOIS Nancy 2017 - Session E-1 - Hépatotoxicité de l’Agomélatine (Valdoxan®) en comparaison des antidépresseurs de la classe des Inhibiteurs Sélectifs de la Recapture de la
-
Journées EMOIS Nancy 2017 - Session F-1- Étude sur la définition clinique de la césarienne en urgen…
Titre : Journées EMOIS Nancy 2017 - Session F-1- Étude sur la définition clinique de la césarienne en urgence et la césarienne programmée dans la région Grand Est, France Intervenant(e)(s) : Aurélie
-
Journées EMOIS Nancy 2017 - Session E-1- Utilisation des données de l’assurance maladie française …
Titre : Journées EMOIS Nancy 2017 - Session E-1- Utilisation des données de l’assurance maladie française pour étudier la qualité des pratiques et la sécurité des soins dans le domaine du médicament
-
Journées EMOIS Nancy 2017 - Session E-1- Les ré-hospitalisations précoces des thromboses veineuses…
Titre : Journées EMOIS Nancy 2017 - Session E-1- Les ré-hospitalisations précoces des thromboses veineuses profondes et des embolies pulmonaires prises en charge dans les hôpitaux publics et privés
-
Journées EMOIS Nancy 2017 - Session E-1- Retour d’expérience HAS sur le complément de validation d…
Titre : Journées EMOIS Session E-1- Nancy 2017 - Retour d’expérience HAS sur le complément de validation d’un indicateur de sécurité du patient Intervenant(e)(s) : Isabelle EVRARD, HAS Programme
-
Journées EMOIS Nancy 2017 - Session E-1 - Attentats de Charlie Hebdo et du 13 novembre 2015: quel i…
Titre : Journées EMOIS Nancy 2017 - Session E-1 -Attentats de Charlie Hebdo et du 13 novembre 2015: quel impact sur les hospitalisations pour maladies cardiovasculaires ? Intervenant(e)(s) : Valérie
-
Journées EMOIS Nancy 2017 - Table Ronde : "Partage des données de santé : nouvelles règles, nouveau…
Titre : Journées EMOIS Nancy 2017 - able Ronde : "Partage des données de santé : nouvelles règles, nouveaux enjeux" Modérateurs : M GOLDBERG, C QUANTIN. Intervenants : Claude GISSOT, Dominique